NCT04575896View on ClinicalTrials.gov

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 20, 2020

Primary Completion Date

November 28, 2023

Study Completion Date

December 1, 2023

Conditions
End Stage Renal DiseaseHepatitis C
Interventions
DRUG

Glecaprevir/pibrentasvir

Glecaprevir/pibrentasvir 300mg/120mg once daily by mouth for 2 weeks post-transplant.

Trial Locations (1)

21205

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT04575896 - Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors | Biotech Hunter | Biotech Hunter